MSLN and neoplasm: In this way, the first phase I clinical trial evaluating CAR T-cells electroporated with mesothelin mRNA demonstrated their effective anti-tumor activity in three patients with malignant pleural mesothelioma (MPM) and one patient with PDAC, while inducing no serious adverse complications, with the exception for incidence of severe anaphylactic reaction in one of the MPM patients (NCT01355965) (55).